PR98187

Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and niche markets.

CASTRES, France and VITROLLES, France, October 10, 2022, PRNewswire=KYODO JBN/--

- Gennisium finds a strategic partner with global experience and connections

in the pharmaceutical industry to accelerate its development in neonatology.

- Pierre Fabre strengthens its activities in the field of rare diseases, and

more specifically pediatric ones.

- This partnership paves the way for further collaboration between the two

companies and marks a milestone for their respective growth strategy in

neonatology/pediatrics, rare diseases and niche/orphan drugs.

The Pierre Fabre Group and Gennisium Pharma have announced an agreement whereby Pierre Fabre

takes a minority stake in Gennisium through its dedicated investment subsidiary

Pierre Fabre Invest.

Gennisium’s company mission is to provide newborn patients with suitable

medicines, based on affordable prices and with global reach. To this end,

Gennisium is looking to reposition known molecules for neonatal indications and

to provide health care professionals and neonatal intensive care units with

novel and suitable formulations along with the medicines they need to prevent

or treat neonatal diseases and conditions.

Franck Pigache, CEO, Gennisium Pharma, commented: “We are very pleased with

this investment and to now have such a strong partner as Pierre Fabre among our

shareholders - a major player and a successful company with solid experience in

the pharmaceutical industry and the specific field of pediatrics. With their

backing, Gennisium will have additional means and latitude to pursue its

growth. New drugs are under development and Pierre Fabre’s investment will

allow us to accelerate the registration and availability of those products.”

Alongside oncology and dermatology, Pierre Fabre is increasingly involved in

the field of rare diseases, with a special focus on diseases affecting

newborns, developing specific and prophylactic therapies for this patient

population in need for adapted treatments. Such is the approach adopted for

infantile hemangioma since 2014 and, more recently, for XLHED, a rare genetic

disease affecting the sweat and respiratory glands, skin, hair and teeth

conditions of baby boys.      

Eric Ducournau, CEO, Pierre Fabre Group, said: “We are delighted to be working

with Gennisium Pharma, a young, innovative pharmaceutical company developing

formulations for premature babies and niche markets. Through this investment,

we confirm our willingness to explore new opportunities in the field of rare

pediatric diseases where patient and family needs remain immense.”

Both companies are already working together to provide this fragile population

of patients with therapeutic advances. By joining forces with Pierre Fabre,

Gennisium finds a strong partner with global experience and connections in the

pharmaceutical industry to accelerate its development in neonatology. Pierre

Fabre will help Gennisium build up its product portfolio, its organization and

its market access across the world, by investing in existing operations,

potential licensing agreements and expertise sharing in the field of

neonatology and pediatrics.

For more information about Pierre Fabre, please visit the website

www.pierre-fabre.com

For more information about Gennisium, please visit the website

https://gennisium.com

Pierre Fabre              

Anne KERVEILLANT

anne.kerveillant@pierre-fabre.com    

Gennisium Pharma

Frank PIGACHE, CEO        

fpigache@gennisium.com

LysAvocat

Siham Belarbi

s.belarbi@lysavocats.com

Logo - https://mma.prnewswire.com/media/1916090/Pierre_Fabre_Gennisium__Logo.jpg

Source: Pierre Fabre, Gennisium